Fourpath Capital Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.26M Buy
44,715
+5,179
+13% +$138K 0.18% 88
2025
Q4
$984K Sell
39,536
-6,133
-13% -$155K 0.13% 102
2025
Q3
$1.16M Buy
45,669
+8,814
+24% +$218K 0.17% 91
2025
Q2
$893K Buy
36,855
+6,095
+20% +$142K 0.14% 101
2025
Q1
$779K Buy
30,760
+7,987
+35% +$209K 0.14% 101
2024
Q4
$604K Sell
22,773
-5,328
-19% -$145K 0.11% 123
2024
Q3
$813K Buy
28,101
+3,425
+14% +$99.9K 0.15% 102
2024
Q2
$690K Sell
24,676
-780
-3% -$21.5K 0.51% 47
2024
Q1
$706K Buy
25,456
+2,838
+13% +$78.8K 0.49% 49
2023
Q4
$651K Sell
22,618
-967
-4% -$29.2K 0.44% 47
2023
Q3
$782K Sell
23,585
-504
-2% -$17.8K 0.59% 36
2023
Q2
$884K Buy
24,089
+3,162
+15% +$123K 1.06% 27
2023
Q1
$854K Buy
20,927
+3,933
+23% +$170K 0.6% 35
2022
Q4
$871K Buy
16,994
+2,218
+15% +$106K 0.63% 39
2022
Q3
$647K Sell
14,776
-966
-6% -$46.9K 0.44% 53
2022
Q2
$825K Sell
15,742
-1,619
-9% -$82.5K 0.51% 45
2022
Q1
$899K Buy
17,361
+4,023
+30% +$209K 0.36% 51
2021
Q4
$788K Buy
+13,338
New +$661K 0.3% 63

Other funds holding PFE

Fourpath Capital Management's PFE Position: Q1 2026 in Review

Fourpath Capital Management increased its Pfizer (PFE) stake by 13% in Q1 2026, buying an estimated $138K and bringing the position to 44,715 shares worth $1.26M. The position accounts for 0.18% of the portfolio, ranked #88.

Fourpath Capital Management first reported a position in PFE in Q4 2021 and has held it in 18 quarters since. 2,934 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Fourpath Capital Management held 44,715 shares of Pfizer worth $1.26M as of Q1 2026.
  • Fourpath Capital Management bought 5,179 Pfizer shares in Q1 2026, an estimated $138K.
  • Pfizer made up 0.18% of Fourpath Capital Management's portfolio in Q1 2026, its #88 holding.
  • Fourpath Capital Management first reported a position in Pfizer in Q4 2021 and has held it in 18 quarters since.
  • 2,934 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Fourpath Capital Management's 13F filing for Q1 2026, filed 1 May 2026.